The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

As CEOs continue to digest the fallout of the murder of UnitedHealthcare CEO Brian Johnson, a billionaire backer of major ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

British drugmaker AstraZeneca has appointed a new China head, replacing a former executive who has been detained by ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

Shares of AstraZeneca PLC AZN inched up 0.25% to £105.38 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.26% to 8,301.62.

Shares of AstraZeneca PLC AZN slid 1.78% to £105.12 Tuesday, on what proved to be an all-around dismal trading session for ...